Identification of serum biomarkers for gastric cancer diagnosis using a human proteome microarray

Lina Yang, Jingfang Wang, Jianfang Li, Hainan Zhang, Shujuan Guo, Min Yan, Zhenggang Zhu, Bin Lan, Youcheng Ding, Ming Xu, Wei Li, Xiaonian Gu, Chong Qi, Heng Zhu, Zhifeng Shao, Bingya Liu, Sheng Ce Tao

Research output: Contribution to journalArticle

Abstract

We aimed to globally discover serum biomarkers for diagnosis of gastric cancer (GC). GC serum autoantibodies were discovered and validated using serum samples from independent patient cohorts encompassing 1,401 participants divided into three groups, i.e. healthy, GC patients, and GC-related disease group. To discover biomarkers for GC, the human proteome microarray was first applied to screen specific autoantibodies in a total of 87 serum samples from GC patients and healthy controls. Potential biomarkers were identified via a statistical analysis protocol. Targeted protein microarrays with only the potential biomarkers were constructed and used to validate the candidate biomarkers using 914 samples. To provide further validation, the abundance of autoantibodies specific to the biomarker candidates was analyzed using enzymelinked immunosorbent assays. Receiver operating characteristic curves were generated to evaluate the diagnostic accuracy of the serum biomarkers. Finally, the efficacy of prognosis efficacy of the final four biomarkers was evaluated by analyzing the clinical records. The final panel of biomarkers consisting of COPS2, CTSF, NT5E, and TERF1 provides high diagnostic power, with 95% sensitivity and 92% specificity to differentiate GC patients from healthy individuals. Prognosis analysis showed that the panel could also serve as independent predictors of the overall GC patient survival. The panel of four serum biomarkers (COPS2, CTSF, NT5E, and TERF1) could serve as a noninvasive diagnostic index for GC, and the combination of them could potentially be used as a predictor of the overall GC survival rate.

Original languageEnglish (US)
Pages (from-to)614-623
Number of pages10
JournalMolecular and Cellular Proteomics
Volume15
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Biomarkers
Proteome
Microarrays
Stomach Neoplasms
Serum
Autoantibodies
Immunosorbents
Protein Array Analysis
ROC Curve
Assays
Statistical methods
Survival Rate
Sensitivity and Specificity

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Analytical Chemistry

Cite this

Identification of serum biomarkers for gastric cancer diagnosis using a human proteome microarray. / Yang, Lina; Wang, Jingfang; Li, Jianfang; Zhang, Hainan; Guo, Shujuan; Yan, Min; Zhu, Zhenggang; Lan, Bin; Ding, Youcheng; Xu, Ming; Li, Wei; Gu, Xiaonian; Qi, Chong; Zhu, Heng; Shao, Zhifeng; Liu, Bingya; Tao, Sheng Ce.

In: Molecular and Cellular Proteomics, Vol. 15, No. 2, 01.02.2016, p. 614-623.

Research output: Contribution to journalArticle

Yang, L, Wang, J, Li, J, Zhang, H, Guo, S, Yan, M, Zhu, Z, Lan, B, Ding, Y, Xu, M, Li, W, Gu, X, Qi, C, Zhu, H, Shao, Z, Liu, B & Tao, SC 2016, 'Identification of serum biomarkers for gastric cancer diagnosis using a human proteome microarray', Molecular and Cellular Proteomics, vol. 15, no. 2, pp. 614-623. https://doi.org/10.1074/mcp.M115.051250
Yang, Lina ; Wang, Jingfang ; Li, Jianfang ; Zhang, Hainan ; Guo, Shujuan ; Yan, Min ; Zhu, Zhenggang ; Lan, Bin ; Ding, Youcheng ; Xu, Ming ; Li, Wei ; Gu, Xiaonian ; Qi, Chong ; Zhu, Heng ; Shao, Zhifeng ; Liu, Bingya ; Tao, Sheng Ce. / Identification of serum biomarkers for gastric cancer diagnosis using a human proteome microarray. In: Molecular and Cellular Proteomics. 2016 ; Vol. 15, No. 2. pp. 614-623.
@article{b1a8214d1327408694094252db5fc034,
title = "Identification of serum biomarkers for gastric cancer diagnosis using a human proteome microarray",
abstract = "We aimed to globally discover serum biomarkers for diagnosis of gastric cancer (GC). GC serum autoantibodies were discovered and validated using serum samples from independent patient cohorts encompassing 1,401 participants divided into three groups, i.e. healthy, GC patients, and GC-related disease group. To discover biomarkers for GC, the human proteome microarray was first applied to screen specific autoantibodies in a total of 87 serum samples from GC patients and healthy controls. Potential biomarkers were identified via a statistical analysis protocol. Targeted protein microarrays with only the potential biomarkers were constructed and used to validate the candidate biomarkers using 914 samples. To provide further validation, the abundance of autoantibodies specific to the biomarker candidates was analyzed using enzymelinked immunosorbent assays. Receiver operating characteristic curves were generated to evaluate the diagnostic accuracy of the serum biomarkers. Finally, the efficacy of prognosis efficacy of the final four biomarkers was evaluated by analyzing the clinical records. The final panel of biomarkers consisting of COPS2, CTSF, NT5E, and TERF1 provides high diagnostic power, with 95{\%} sensitivity and 92{\%} specificity to differentiate GC patients from healthy individuals. Prognosis analysis showed that the panel could also serve as independent predictors of the overall GC patient survival. The panel of four serum biomarkers (COPS2, CTSF, NT5E, and TERF1) could serve as a noninvasive diagnostic index for GC, and the combination of them could potentially be used as a predictor of the overall GC survival rate.",
author = "Lina Yang and Jingfang Wang and Jianfang Li and Hainan Zhang and Shujuan Guo and Min Yan and Zhenggang Zhu and Bin Lan and Youcheng Ding and Ming Xu and Wei Li and Xiaonian Gu and Chong Qi and Heng Zhu and Zhifeng Shao and Bingya Liu and Tao, {Sheng Ce}",
year = "2016",
month = "2",
day = "1",
doi = "10.1074/mcp.M115.051250",
language = "English (US)",
volume = "15",
pages = "614--623",
journal = "Molecular and Cellular Proteomics",
issn = "1535-9476",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "2",

}

TY - JOUR

T1 - Identification of serum biomarkers for gastric cancer diagnosis using a human proteome microarray

AU - Yang, Lina

AU - Wang, Jingfang

AU - Li, Jianfang

AU - Zhang, Hainan

AU - Guo, Shujuan

AU - Yan, Min

AU - Zhu, Zhenggang

AU - Lan, Bin

AU - Ding, Youcheng

AU - Xu, Ming

AU - Li, Wei

AU - Gu, Xiaonian

AU - Qi, Chong

AU - Zhu, Heng

AU - Shao, Zhifeng

AU - Liu, Bingya

AU - Tao, Sheng Ce

PY - 2016/2/1

Y1 - 2016/2/1

N2 - We aimed to globally discover serum biomarkers for diagnosis of gastric cancer (GC). GC serum autoantibodies were discovered and validated using serum samples from independent patient cohorts encompassing 1,401 participants divided into three groups, i.e. healthy, GC patients, and GC-related disease group. To discover biomarkers for GC, the human proteome microarray was first applied to screen specific autoantibodies in a total of 87 serum samples from GC patients and healthy controls. Potential biomarkers were identified via a statistical analysis protocol. Targeted protein microarrays with only the potential biomarkers were constructed and used to validate the candidate biomarkers using 914 samples. To provide further validation, the abundance of autoantibodies specific to the biomarker candidates was analyzed using enzymelinked immunosorbent assays. Receiver operating characteristic curves were generated to evaluate the diagnostic accuracy of the serum biomarkers. Finally, the efficacy of prognosis efficacy of the final four biomarkers was evaluated by analyzing the clinical records. The final panel of biomarkers consisting of COPS2, CTSF, NT5E, and TERF1 provides high diagnostic power, with 95% sensitivity and 92% specificity to differentiate GC patients from healthy individuals. Prognosis analysis showed that the panel could also serve as independent predictors of the overall GC patient survival. The panel of four serum biomarkers (COPS2, CTSF, NT5E, and TERF1) could serve as a noninvasive diagnostic index for GC, and the combination of them could potentially be used as a predictor of the overall GC survival rate.

AB - We aimed to globally discover serum biomarkers for diagnosis of gastric cancer (GC). GC serum autoantibodies were discovered and validated using serum samples from independent patient cohorts encompassing 1,401 participants divided into three groups, i.e. healthy, GC patients, and GC-related disease group. To discover biomarkers for GC, the human proteome microarray was first applied to screen specific autoantibodies in a total of 87 serum samples from GC patients and healthy controls. Potential biomarkers were identified via a statistical analysis protocol. Targeted protein microarrays with only the potential biomarkers were constructed and used to validate the candidate biomarkers using 914 samples. To provide further validation, the abundance of autoantibodies specific to the biomarker candidates was analyzed using enzymelinked immunosorbent assays. Receiver operating characteristic curves were generated to evaluate the diagnostic accuracy of the serum biomarkers. Finally, the efficacy of prognosis efficacy of the final four biomarkers was evaluated by analyzing the clinical records. The final panel of biomarkers consisting of COPS2, CTSF, NT5E, and TERF1 provides high diagnostic power, with 95% sensitivity and 92% specificity to differentiate GC patients from healthy individuals. Prognosis analysis showed that the panel could also serve as independent predictors of the overall GC patient survival. The panel of four serum biomarkers (COPS2, CTSF, NT5E, and TERF1) could serve as a noninvasive diagnostic index for GC, and the combination of them could potentially be used as a predictor of the overall GC survival rate.

UR - http://www.scopus.com/inward/record.url?scp=84957916873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957916873&partnerID=8YFLogxK

U2 - 10.1074/mcp.M115.051250

DO - 10.1074/mcp.M115.051250

M3 - Article

C2 - 26598640

AN - SCOPUS:84957916873

VL - 15

SP - 614

EP - 623

JO - Molecular and Cellular Proteomics

JF - Molecular and Cellular Proteomics

SN - 1535-9476

IS - 2

ER -